The substantial induction of genes typical of noradrenergic differentiation does not translate directly to a tumor suppressive role but in combination with reduced proliferation, reduced MYCN levels, impaired tumor growth and the pattern in several hundreds of tumors as well as several thousand single tumor cells from patients, it challenges the predominant view that HIF2α is an oncogene. The gene discussed is EPAS1; the disease is neoplasm.